Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04186273
Other study ID # H16-02491
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 5, 2019
Est. completion date March 1, 2021

Study information

Verified date December 2019
Source University of British Columbia
Contact Anthony Papp, MD, PhD
Phone 1.778.362.0161
Email anthony.papp@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will investigate the safety and effectiveness of daily post surgical scar management, using a moisture-balancing base product containing different amounts of a novel (NCE) antifibrogenic compound FS2, a natural metabolite of the kynurenine pathway. Results of recent peer-reviewed, pre-clinical evidence warrant further investigation to validate therapeutic scar preventive efficacy of topically administered/delivered FS2. There are no known safety concerns with current product formulations. Recent Phase I clinical safety and tolerability data further support continuation of the research proposed in this study.


Description:

Study Arms (Investigational Conditions):

Total of 6, categorized by type of wound and treatment allocation.

Description of Study Arms:

The quality of tissue repair and scarring will be evaluated in two different, bisected post-surgical sites on the same Participant. Each wound site represents a Study Arm. Each wound site will receive two treatments, one of which is always a vehicle. In total the two wound types provide a total of 6 Study Arms for statistical analysis.

Arm 1 / Wound Type 1 (skin grafted wounds: 3-treatment groups): The wound site (injury) that requires skin grafting surgery to remove normal, uninjured skin from the same Participant to cover and repair a deep wound (a "skin graft").

Arm 2 / Wound Type (donor skin graft harvest site; 3-treatment groups): A surgical wound where a piece of normal skin is removed at uniform depth using a dermatome to harvest a skin graft ("skin graft harvest site").

The bisected wound site is randomly assigned either a control or FS2 cream treatment.

Treatment Groups: Each wound site will be used to investigate and compare three different treatments. Participants will apply the investigated treatments ("IP") as directed to allocated bisected sections of the skin grafted wound and donor wound site for 90 days. Follow-on assessments will be conducted with additional study visits on Days 180 and 270 (study endpoint).

There are four (4) differently labelled products as follows:

Treatment-1 (IP1) A single, daily application of a moisturizing cream-base.

Treatment-2 (IP2) A single, daily application of a moisturizing cream-base with FS2 (0.50% w/w).

Treatment-3 (IP3) A single, daily application of a moisturizing cream-base with FS2 (0.25% w/w). IP3 will have two different product labels to conceal the identity of the vehicle.

Control-cream (IP1), and treatments IP2 and IP3 each containing 0.50%w/w or 0.25%w/w FS2 respectively, will be topically applied to designated treatment sites once per day for a period of 90 days. Investigator and participant will be blinded from both identity of treatment product and randomized location. Each participant will be provided a different cream for each bisected-site for a total of four (4) differently labelled creams; two for the donor site, and two for the skin grafted site. Participants will discuss and be informed/reminded at each visit about study design, responsibilities, possible adverse events, proper daily wound care and cream application methods.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date March 1, 2021
Est. primary completion date February 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Medically able to consent to study requirements

2. Adult, male and female trauma patients

3. Ages 18 to 65 years of age

4. Fluent in English (able to consent without a translator)

5. Isolated skin wound of 3% Total Body Surface Area

6. Participant requires partial thickness skin graft (meshed/non-meshed), face and genitalia excluded.

7. Grafted skin is between 100 cm2 and 600 cm2

8. Maximum skin graft expansion ratio is 1:1.5

Exclusion Criteria:

1. Medically unable to consent to study requirements

2. Require an English translator to lawfully consent to the study and its requirements

3. Treatment sights (skin graft sights) located on the face and genitalia

4. Expected to be medically unstable for the duration of the study period and an additional 1-month thereafter

5. Pregnant, or attempting to become pregnant

6. Known immunosuppression or immunosuppressive illness

7. Subjects who had taken part in a clinical trial within 3 months prior to admission to this trial or who are currently participating in a clinical trial, whether an investigational drug was used or not.

8. Subjects who had any clinical evidence of severe ongoing or prolonged depression or mental illness

9. Subjects who smoke more than 20 cigarettes a day

10. Subjects who demonstrated evidence of drug abuse

11. Any other diagnosis, condition, physical or geographical limitation with the participant that may render, or increases the likelihood of rendering, him/her unable to complete the entire study.

Study Design


Intervention

Drug:
Fibrosis-Inhibiting-Compound-FS2
There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
Other:
Vehicle moisture balancing base
Vehicle base without FS2.

Locations

Country Name City State
Canada VGH Burn Unit Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Papp A, Hartwell R, Evans M, Ghahary A. The Safety and Tolerability of Topically Delivered Kynurenic Acid in Humans. A Phase 1 Randomized Double-Blind Clinical Trial. J Pharm Sci. 2018 Jun;107(6):1572-1576. doi: 10.1016/j.xphs.2018.01.023. Epub 2018 Feb 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Vancouver Scar Scale (VSS) Differences in clinical scale scoring of healing, complications and scar severity using Vancouver Scar Scale. Investigator assessment of target scar or keloid using the Vancouver Scar Scale (VSS). Scale parameters include: Pigmentation (0-2), Vascularity (0-3), Pliability (0-5), and Height (0-3). Scale measurements include: minimum score of 0 = normal to a maximum score of 2, 3 or 5 depending on the parameter measured. 0-9 months
Primary Patient and Observer Scar Assessment Scale (POSAS) Differences in clinical scale scoring of healing, complications and scar severity using Patient and Observer Scar Assessment Scale (POSAS). Investigator assessment of target scar or keloid using the Patient and Observer Scar Assessment Scale (POSAS). Scale parameters include: Vascularity, Pigmentation, Thickness, Relief, Pliability, and Surface Area. Scale measurements include: minimum score of 1 = normal skin to a maximum score of 10 = worst scar imaginable. 0-9 months
Secondary Adverse Events To evaluate and compare Treatment safety by the proportion of adverse events in each treatment arm. 0-9 months
Secondary Vital Signs - systolic blood pressure To evaluate and compare Treatment safety by the proportion of abnormal systolic blood pressures in each participant. 0-9 months
Secondary Vital Signs - diastolic blood pressure To evaluate and compare Treatment safety by the proportion of abnormal diastolic blood pressures in participant. 0-9 months
Secondary Vital Signs - Heart Rate To evaluate and compare Treatment safety by the proportion of abnormal heart rates in each participant. 0-9 months
Secondary Vital Signs - Respiratory Rate To evaluate and compare Treatment safety by the proportion of abnormal respiratory rates in each participant. 0-9 months
Secondary Vital Signs - Oral Temperature To evaluate and compare Treatment safety by the proportion of abnormal temperatures in each participant. 0-9 months
Secondary Physical Exam Findings To evaluate and compare Treatment safety by the proportion of abnormal physical exam findings in each participant. 0-9 months
Secondary Clinical Chemistry Results To evaluate and compare Treatment safety by the proportion of abnormal clinical chemistry results in each participant. 0-9 months
Secondary Hematology Results To evaluate and compare Treatment safety by the proportion of abnormal hematology results for each participant. 0-9 months
Secondary Urine Analysis Results To evaluate and compare Treatment safety by the proportion of abnormal urine analysis results for each participant. 0-9 months
Secondary FS2 Pharmacokinetic urine analysis data To obtain, evaluate and compare total urine drug concentrations for each participant and compare clearance normalized by estimated volume of distribution (Vd). 0-2 hours; 0-9 months
Secondary FS2 Pharmacokinetic blood analysis data To obtain, evaluate and compare total blood drug concentrations for each participant and compare clearance normalized by estimated volume of distribution (Vd). 0-2 hours; 0-9 months
Secondary Pain Management Pain Visual Analog Scale longitudinal comparison of subjective changes for each participant.
Pain, Visual analog scale (score 0-none to 10-worse)
0-9months
Secondary Histology (Tissue Biopsies) Evaluate and compare pathological assessments of punch biopsies obtained from each treatment site and compare intra site subjective findings (qualitative) for each. 3 months and 9 months
Secondary Histology (Tissue Biopsies) Evaluate and compare intra site scar elevation index ratios (comparative ratio of normal skin dimensions (e.g. thickness) to those of an adjacent scar). Assessment requires histology sections of punch biopsies obtained from each treatment site and further substantiates Outcome 16 above. 3 months and 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Completed NCT01706848 - Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound N/A
Recruiting NCT01177358 - Botox in the Healing of Surgical Wounds of the Neck Phase 2
Terminated NCT01459666 - Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Phase 4
Completed NCT00970671 - Treatment of Surgical Scars Using the Pulsed Dye Laser N/A
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Completed NCT05293652 - Effect of Hydrocortisone Iontophoresis Versus Hydrocortisone Phonophoresis On Post Surgical Scar N/A
Recruiting NCT03406143 - Evaluation of the Effect of CGF in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration N/A
Completed NCT05527756 - Evaluation of the Cosmetic Outcomes of Totally Endoscopic Cardiac Surgery
Completed NCT02886988 - Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection Phase 2/Phase 3
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Recruiting NCT05408117 - Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color N/A
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Terminated NCT02520557 - An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
Not yet recruiting NCT04621994 - Cesarean Wound Closure: Dermabond Versus Steri Strips N/A
Withdrawn NCT03395678 - Acne Scarring in Skin of Color: Laser vs Microneedling N/A
Completed NCT02744950 - Comparison of Scar Results and Time for Closures of Scalp Defects Via Pulley Sutures or Layered Repairs N/A
Not yet recruiting NCT01005992 - Fractional Photothermolysis for the Treatment of Burn Scars Phase 1
Completed NCT04870008 - Aesthetic Outcome of Running Cuticular Suture Distance (2mm vs 5mm) N/A
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A